Publix Pharmacy Provides Savings on Certain GLP-1 Medications
LAKELAND, Fla.--(BUSINESS WIRE)-- Publix Pharmacy is currently offering savings on select GLP‑1 therapies through a discount card program. For a limited time, eligible Publix Pharmacy customers can have their prescriptions for the newly introduced Wegovy (semaglutide) 1.5 mg or 4 mg tablet filled at pricing starting as low as $149 per month, and Wegovy and Ozempic (semaglutide) 0.25 mg and 0.5 mg injectables starting as low as $199 per month.
Obtaining the reduced price
Customers can speak with their Publix Pharmacist to learn offer details, current pricing and ways to lower their out-of-pocket costs for these and other prescription medications.
Prices and availability can change at any time. Pricing available through the use of discount cards is subject to the terms and conditions of the offer or discount card. A valid prescription is required. Use of discount cards may preclude the use of other insurance, federal programs or additional discounts.
Publix, the largest employee-owned company in the U.S. with more than 260,000 associates, currently operates 1,432 stores in Florida, Georgia, Alabama, Tennessee, South Carolina, North Carolina, Virginia and Kentucky. For 28 consecutive years, the company has been recognized by Fortune as a great place to work. In addition, Publix’s dedication to superior quality and customer service is recognized among the top in the grocery business. For more information, visit the company’s newsroom at corporate.publix.com/newsroom.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260203756538/en/
Maria Brous
(863) 680-5339
Source: Publix
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rio Tinto celebrates 60 years in Western Australia
- Battery X Metals Provides Board of Directors Update
- Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Create E-mail Alert Related Categories
Business Wire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share